On ECHEMI
Home > Drugs > Progressive hemifacial atrophy
Progressive hemifacial atrophy
Progressive hemifacial atrophy is also known as Parry-Romberg syndrome. It is a progressive unilateral facial tissue nutritional disorder. In a few cases, the lesions involve the limbs or the trunk, which is called progressive hemifacial atrophy. Its clinical features are the chronic progressive atrophy of subcutaneous fat and connective tissue on one side of the face. The muscle fibers are not affected. In severe cases, the cartilage and bones are invaded. Most scholars believe that this disease is related to sympathetic nerve dysfunction. Sympathetic nerve damage caused by various reasons causes neurotrophic disorders of facial tissue, which eventually leads to facial tissue atrophy. Other theories involve local or systemic infection, injury, trigeminal neuritis, connective tissue disease, genetic degeneration, etc. The speed of disease progression is uncertain. Most cases tend to improve after several years to more than ten years, but the associated epilepsy may continue.
  • Site of disease:

    Face
  • Infectious :

    Not contagious
  • Frequent population:

    Adolescents before 20 years old, more common in females
  • Related symptoms:

    Twitching dry skin hair loss unilateral facial atrophy skin atrophy and pigmentation
  • Concurrent disease:

Related Drugs
Anisodine Hydrobromide Tablets
Indication: It is used to treat migraine, vascular headache, retinal vasospasm, ischemic optic neuropathy, acute paralysis and tremor paralysis caused by nervous system inflammation and cerebral vascular diseases. It is also used for the detoxification of organophosphate pesticide poisoning.
Manufacturer:

Chengdu First Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.